Liquid Biopsy Market (By Technology: PCR and NGS; By Application: Cancer and Non-Cancer; By Circulating Biomarker: Circulating Tumor Cells, Cell-Free DNA, Circulating Tumor DNA, Extracellular Vesicles, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 - 2030


The global liquid biopsy market was valued at USD 7.1 billion in 2020 and is projected to surpass USD 26.2 billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 14% during the forecast period 2021 to 2030.

Liquid Biopsy Market Size, 2020 to 2030

Growth Factors

The global liquid biopsy market is primarily driven by the rising prevalence of cancer among the global population and rising awareness regarding the availability of different non-invasive treatments. As per the data provided by the International Agency for Research on Cancer in the GLOBOCAN 2020 estimates, around 19.3 million new cases of cancer and around 10 million deaths were reported due to cancer in 2020. The rising prevalence of breast cancer among the female population has made it the most common type of cancer diagnosed across the globe. In 2020, around 2.3 million new breast cancer cases were recorded, closely followed by the lungs cancer, colorectal cancer, and prostate cancer. Cancer is the second most leading cause of death across the globe, as per the World Health Organization. There are several benefits associated with the new liquid biopsy technique such as rapid results, low cost, early prognosis, overcoming tumor heterogeneity, low risk, and non-invasiveness. All these benefits of the liquid biopsy over the traditional diagnosis is fueling the adoption of the liquid biopsy among the patients across the globe, and is expected to significantly drive the demand during the forecast period.

The increased awareness about the cancer is boosting the liquid biopsy market growth as liquid biopsy technique can detect the cancer early, can monitor progression of tumor, and can assess clinical prognosis. Moreover, the proliferation of advanced technologies has boosted the demand for the non-invasive diagnosis and treatments that is expected to spur the demand for the liquid biopsy in the forthcoming years. The rising investments by the market players in the clinical trials for the development of innovative diagnostic solutions is exponentially contributing towards the market growth.

Scope of the Liquid Biopsy Market Report

Report Highlights Details
Market Size in 2030 USD 26.2 Billion
Growth Rate CAGR of 14% From 2021 to 2030
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2021
Forecast Period 2021 to 2030
By Technology
  • PCR
  • NGS
Regional Scope
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
Companies Mentioned Bio-Rad Laboratories, Biocept Inc., Guardant Health, QIAGEN N.V, Illumina, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, Thermo Fisher Scientific Inc.

 

Technology Insights

Based on the technology, the multi-gene parallelanalysis (NGS) segment accounted 74% revenue share in 2020. This is attributed to the higher efficiency of the NGS technology to detect even the lower frequency variants of cancer. The advancements in the NGS has resulted in the increased adoption of this technology as it can detect rare and novel mutations of cancer easily.

On the other hand, the PCR is estimated to be the most opportunistic segment during the forecast period. The adoption of PCR is rising owing to its rising uses for numerous purposes such as detecting fungal infections, bacterial infections, gene mapping, and other genomic applications. The quick and real-time diagnostic results provided by the PCR tests is accurate and it can guide the targeted therapies for the cancer treatment. The PCR is gaining immense popularity and is expected to witness a significant growth rate in the upcoming years.

Application Insights

Based on the application, the cancer segment dominated the global liquid biopsy market in 2020, in terms of revenue and is estimated to sustain its dominance during the forecast period. This is simply attributed to the increased adoption of the liquid biopsy techniques for the diagnosis of various types of cancer. The increased prevalence of cancer cases among the global population has boosted the growth of the cancer segment. According to the International Agency for Research on Cancer, the most prevalent types of cancer includes lungs cancer, breast cancer, prostate cancer, and colorectal cancer. The cancer cases across the globe is estimated to rise by 47% from 2020 to 2040, and the number of cancer cases are estimated to be 28.4 million by 2040 across the globe. Hence, this is expected to sustain the significance of this segment throughout the forecast period.

Circulating Biomarker Insights

Based on the circulating biomarker, the circulating tumor cells segment dominated the market with the revenue share of 36.5% in 2020. The circulating tumor cells have gained rapid traction in the market as the liquid biopsy is considered as the most reliable method of detecting circulating tumor cells. Moreover, it facilitates in cancer prognosis, and can guide in the cancer therapeutics and monitor therapeutic regimens.

On the other hand, the circulating tumor DNA is expected to be the fastest-growing segment during the forecast period. The circulating tumor DNA helps in the early detection of the cancer and its mutation. It is most efficient in detection of the breast cancer. Therefore, the rising prevalence of breast cancer is expected to boost the growth of this segment. As per the GLOBOCAN report, breast cancer has surpassed the lungs cancer as the most diagnosed type of cancer across the globe in 2020.

Region Insights

Based on region, North America held the revenue share of 50% in 2020. This is mainly due to the increased adoption of the liquid biopsy in the North American region for the diagnosis of cancer. The rapidly growing cases of cancer in the huge market like US has resulted in the dominance of this region in the global liquid biopsy market. According to the American Cancer Society, in 2020, there were around 1.8 million new cancer cases were estimated in US.

On the other hand, Asia Pacific is estimated to be the fastest-growing market during the forecast period. Asia Pacific is characterized by the increasing disposable income, increasing healthcare expenditure, rising awareness regarding the liquid biopsy techniques, and rising adoption of the advanced techniques in the hospitals, clinics, and diagnostic laboratories for the diagnosis. The growing penetration of hospitals and diagnostic centers in the region is expected to fuel the growth of the liquid biopsy market during the forthcoming years.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

In June 2021, Biocept Inc. and Quest Diagnostics collaborated to develop an advanced NGS testing technology especially for the lungs cancer patients.

The various developmental strategies like new product launches,partnerships, and collaboration fosters market growth and offers lucrative growth opportunities to the market players.

Some of the prominent players in the global liquid biopsy market include:

  • Bio-Rad Laboratories
  • Biocept Inc.
  • Guardant Health
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Laboratory Corporation of America Holdings
  • MDxHealth SA
  • QIAGEN N.V
  • Thermo Fisher Scientific Inc.

Segments Covered in the Report

By Technology

  • PCR
  • NGS

By Application

  • Cancer
    • Lungs Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others
  • Non-Cancer

By Circulating Biomarker

  • Circulating Tumor Cells
  • Cell-Free DNA
  • Circulating Tumor DNA
  • Extracellular Vesicles
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Frequently Asked Questions

How much is the liquid biopsy market size?
According to Precedence Research, the global liquid biopsy market size was reached at USD 7.1 billion in 2020 and is predicted to reach USD 26.2 billion by 2030.
The global liquid biopsy market is growing at a CAGR of 14% during the forecast period 2021 to 2030.
The rapidly growing number of deaths linked to cancer and rising burden of various types of cancer such as neck and head cancer, colorectal cancer, lungs cancer, breast cancer, and bowel cancer is poised to boost the growth of the global liquid biopsy market in the upcoming years.
The top key players operating in the liquid biopsy market are Bio-Rad Laboratories, Biocept Inc., Guardant Health, QIAGEN N.V, Illumina, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, Thermo Fisher Scientific Inc..
North America dominated the global liquid biopsy market in 2020 and will lead the market in near future.

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample